BIOLASE (NASDAQ:BIOL) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Saturday. The firm set a “sell” rating on the medical technology company’s stock.

BIOLASE Stock Performance

Shares of BIOL opened at $0.15 on Friday. The company’s 50 day simple moving average is $0.15 and its 200-day simple moving average is $0.74. BIOLASE has a 12-month low of $0.13 and a 12-month high of $32.09. The company has a current ratio of 1.26, a quick ratio of 0.68 and a debt-to-equity ratio of 34.06. The firm has a market cap of $4.83 million, a PE ratio of 0.00 and a beta of 0.71.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share (EPS) for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%. The business had revenue of $13.49 million for the quarter.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.